Infrastructure for new drug development to treat muscular dystrophy: Current status of patient registration (Remudy)

Brain and Nerve

Volumn 63, Issue 11, 2011, Pages 1279-1284

  Nakamura, Harumasa ^a   Kimura, En ^b   Kawai, Mitsuru ^c  

^a National Center Hospital of Neurology and Psychiatry   (Japan)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^c Higashisaitama National Hospital   (Japan)

Author keywords

Databese; Dystrophinopathy; Orphan drug; Remudy; TREAT NMD

Indexed keywords

BECKER MUSCULAR DYSTROPHY; CLINICAL TRIAL (TOPIC); DATA BASE; DRUG DEVELOPMENT; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; JAPANESE; MEDICAL INFORMATION SYSTEM; MOLECULAR GENETICS; PATIENT INFORMATION; PATIENT PARTICIPATION; PATIENT SELECTION; REGISTER; REVIEW;

CLINICAL TRIALS AS TOPIC; DATABASES AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; JAPAN; MUSCULAR DYSTROPHY, DUCHENNE; REGISTRIES;

EID: 82155202996     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Davies KE, Smith TJ, Bundey S, Read AP, Fint T, et al.: Mild and severe muscular dystrophy associated with deletions in Xp21 of the human X chromosome. J Med Genet 25: 9-13, 1988 (Pubitemid 18042294)
2. Nelson SF, Crosbie RH, Miceli MC, Spencer MJ: Emerging genetic therapies to treat Duchenne muscu-lar dystrophy. Curr Opin Neurol 22: 532-538, 2009
3. ClinicalTrials.gov Identifier: NCT00159250
4. Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, et al.: Local dystrophin restoration with antisense oligonucleotide PRO051.van. N Engl J Med 357: 2677-2686, 2007
5. ClinicalTrials.gov Identifier: NCT01153932
6. ClinicalTrials.gov Identifier: NCT00592553
7. TREAT-NMD: http://www.treat-nmd.eu/home.php
8. Brabec P, Vondrácek P, Klimes D, Baumeister S, Lochmüller H, et al.: Characterization of the DMD/BMD patient population in Czech Republic and Slovakia using an innovative registry approach. Neuromuscul Disord 19: 250-254, 2009
9. Takeshima Y, Yagi M, Okizuka Y, Awano H, Zhang Z, et al.: Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. J Hum Genet 55: 379-388, 2010
10. Remudy: http://www.remudy.jp/
11. Ichimaru K, Toyoshima S, Uyama Y: Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors. Clin Pharmacol Ther 87: 362-366, 2010
12. GlaxoSmithKline: http://www.gsk-clinicalstudyregister.com/protocol-comp- list.jsp?compound=GSK2402968